Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

References

• OwenMJSawaAMortensenPBSchizophreniaLancet201638810039869726777917
   PubMed Web of Science ®Google Scholar
• MandelliLToscanoEPorcelliSFabbriCSerrettiAAge of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental FactorsPsychiatry Investig2016132247249
   Web of Science ®Google Scholar
• StahlSMMorrissetteDACitromeL“Meta-guidelines” for the management of patients with schizophreniaCNS Spectr201318315016223591126
   PubMed Web of Science ®Google Scholar
• HoyerCKranasterLLewekeFMKlosterkötterJMeyer-LindenbergAKoetheDFamilial differential treatment response in schizophrenia – lessons from a case of three affected siblingsPharmacopsychiatry201043519619720191444
   PubMed Web of Science ®Google Scholar
• MarkovićJPlesticSKosticJConcordant response to pharmacotherapy in monozygotic twins with schizoaffective disorderEur Rev Med Pharmacol Sci201317233262326424338471
   PubMed Web of Science ®Google Scholar
• PougetJGShamsTATiwariAKMüllerDJPharmacogenetics and outcome with antipsychotic drugsDialogues Clin Neurosci201416455556625733959
   PubMed Web of Science ®Google Scholar
• LallyJMaccabeJHAntipsychotic medication in schizophrenia: a reviewBr Med Bull2015114116917925957394
   PubMed Web of Science ®Google Scholar
• ScharfetterJPharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an updatePharmacogenomics20045669169815335289
   PubMed Web of Science ®Google Scholar
• ZhangJPMalhotraAKPharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionExpert Opin Drug Metab Toxicol20117193721162693
   PubMed Web of Science ®Google Scholar
• SuzukiAKondoTMiharaKAssociation between Taq1 a dopamine D2 receptor polymorphism and psychopathology of schizophrenia in Japanese patientsProg Neuropsychopharmacol Biol Psychiatry20002471105111311131175
   PubMed Web of Science ®Google Scholar
• HwangRShinkaiTde LucaVAssociation study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populationsPsychopharmacology2005181117918715830237
   PubMed Web of Science ®Google Scholar
• VijayanNNBhaskaranSKoshyLVAssociation of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian populationBehav Brain Funct20073343417651483
   PubMed Web of Science ®Google Scholar
• ZhangJPLenczTMalhotraAKD2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysisAm J Psychiatry2010167776377220194480
   PubMed Web of Science ®Google Scholar
• XingQQianXLiHThe relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patientsInt J Neuropsychopharmacol200710563163717105675
   PubMed Web of Science ®Google Scholar
• IkedaMYamanouchiYKinoshitaYVariants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophreniaPharmacogenomics20089101437144318855532
   PubMed Web of Science ®Google Scholar
• FijalBAKinonBJKapurSCandidate-gene association analysis of response to risperidone in African-American and white patients with schizophreniaPharmacogenomics J20099531131819451915
   PubMed Web of Science ®Google Scholar
• NuntamoolNNgamsamutNVanwongNPharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and AdolescentsBasic Clin Pharmacol Toxicol2017121431632428470827
   PubMed Web of Science ®Google Scholar
• HoustonJDhariaSBishopJRAssociation of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated womenPsychiatry Res20111871–2747921095016
   PubMed Web of Science ®Google Scholar
• ScharfetterJChaudhryHRHornikKDopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patientsEur Neuropsychopharmacol1999101172010647091
   PubMed Web of Science ®Google Scholar
• HwangRZaiCTiwariAEffect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variantPharmacogenomics J201010320021820029384
   PubMed Web of Science ®Google Scholar
• LaneHYHsuSKLiuYCDopamine D3 receptor Ser9Gly polymorphism and risperidone responseJ Clin Psychopharmacol200525161115643094
   PubMed Web of Science ®Google Scholar
• AdamsDHSandraCFarmenMDowningAMBreierAHoustonJPDopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately Ccaucasian patients with chronic schizophrenia or schizoaffective disorderHum Psychopharmacol200823426727418320559
   PubMed Web of Science ®Google Scholar
• SzekeresGKériSJuhászARole of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophreniaAm J Med Genet B Neuropsychiatr Genet2004124B11514681904
   PubMed Web of Science ®Google Scholar
• VehofJBurgerHWilffertBClinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genesEur Neuropsychopharmacol201222962563122386772
   PubMed Web of Science ®Google Scholar
• IlliAMattilaKMKampmanOCatechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophreniaJ Clin Psychopharmacol200323542943414520117
   PubMed Web of Science ®Google Scholar
• IlliAKampmanOHänninenKCatechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophreniaHum Psychopharmacol200722421121517526059
   PubMed Web of Science ®Google Scholar
• HuangEZaiCCLisowayACatechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysisInt J Neuropsychopharmacol2016195pyv1321226745992
   PubMed Web of Science ®Google Scholar
• BobesJA Spanish validation study of the mini international neuropsychiatric interviewEuropean Psychiatry199813198s199s
   PubMed Web of Science ®Google Scholar
• O’DonnellCDonohoeGSharkeyLCompliance therapy: a randomised controlled trial in schizophreniaBMJ2003327741983414551096
   PubMed Web of Science ®Google Scholar
• HaroJMKamathSAOchoaSThe Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand2003107s4161623
   Web of Science ®Google Scholar
• FongTCHoRTWanAHSiuPJAu-YeungFSPsychometric validation of the consensus five-factor model of the Positive and Negative Syndrome ScaleCompr Psychiatry20156220420826343485
   PubMed Web of Science ®Google Scholar
• SuzukiTRemingtonGMulsantBHDefining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendationPsychiatry Res20121971–21622429484
   PubMed Web of Science ®Google Scholar
• MouaffakFKebirOChayetMAssociation of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophreniaPharmacogenomics J201111426727320531374
   PubMed Web of Science ®Google Scholar
• SeemanMVGender Differences in the Prescribing of Antipsychotic DrugsAm J Psychiatry200416181324133315285956
   PubMed Web of Science ®Google Scholar
• CanusoBCMPandina G. Gender and SchizophreniaPsychopharmacol Bull200740417819018227787
   PubMed Web of Science ®Google Scholar
• YamanakaHKanaharaNSuzukiTImpact of dopamine super-sensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosisSchizophr Res20161702–325225826775264
   PubMed Web of Science ®Google Scholar
• ShiYLiMSongCCombined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patientsTransl Psychiatry201777e117028696411
   PubMed Web of Science ®Google Scholar
• XuQWuXLiMAssociation studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han populationPharmacogenomics J201616435736526282453
   PubMed Web of Science ®Google Scholar
• MoleroPOrtuñoFZalacainMPatiño-GarcíaAClinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatmentPharmacogenomics J20077641842617363961
   PubMed Web of Science ®Google Scholar
• KangCYXuXFShiZYYangJZLiuHXuHHInteraction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophreniaPsychiatry Res20101761949520053459
   PubMed Web of Science ®Google Scholar
• GuptaMBhatnagarPGroverSAssociation studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatmentPharmacogenomics200910338539719290789
   PubMed Web of Science ®Google Scholar
• GaoSHuZChengJImpact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significanceClin Biochem20124510–1178779222560999
   PubMed Web of Science ®Google Scholar
• LenczTRobinsonDGXuKDRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patientsAm J Psychiatry2006163352953116513877
   PubMed Web of Science ®Google Scholar
• MaLZhangXXiangQAssociation between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysisBasic Clin Pharmacol Toxicol Epub2018813
   Web of Science ®Google Scholar
• ShaikhSCollierDAShamPCAllelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophreniaHum Genet19969767147198641685
   PubMed Web of Science ®Google Scholar
• GressierFPorcelliSCalatiRSerrettiAPharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysisEur Neuropsychopharmacol201626216318526792444
   PubMed Web of Science ®Google Scholar
• HwangRShinkaiTde LucaVAssociation study of four dopamine D1 receptor gene polymorphisms and clozapine treatment responseJ Psychopharmacol200721771872717092969
   PubMed Web of Science ®Google Scholar
• EbsteinRPMacciardiFHeresco-LeviUEvidence for an association between the dopamine D3 receptor gene DRD3 and schizophreniaHum Hered19974716169017973
   PubMed Web of Science ®Google Scholar
• ReynoldsGPYaoZZhangXSunJZhangZPharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom responseEur Neuropsychopharmacol200515214315115695058
   PubMed Web of Science ®Google Scholar